BioVex Closes Series E

BioVex Inc., a Woburn, Mass.�based drug company whose lead candidate is designed to help treat advanced melanoma, has closed its Series E round with a total of $35 million. It had announced a $22 million first close earlier this year, and the final close includes some venture debt from Oxford Finance Corp. and Silicon Valley Bank.

Triathlon Medical Ventures led the overall round, and was joined by New Science Ventures, Harris and Harris Group and return backers ABN Amro, Avalon Ventures, Credit Agricole Private Equity, GeneChem Management, Innoven Partners and Scottish Equity Partners.